6.16
+0.195(+3.27%)
Currency In USD
| Previous Close | 5.96 |
| Open | 5.9 |
| Day High | 6.36 |
| Day Low | 5.9 |
| 52-Week High | 30.9 |
| 52-Week Low | 3.82 |
| Volume | 39,414 |
| Average Volume | 51,148 |
| Market Cap | 58.14M |
| PE | -0.8 |
| EPS | -7.74 |
| Moving Average 50 Days | 6.65 |
| Moving Average 200 Days | 6.94 |
| Change | 0.2 |
If you invested $1000 in Verrica Pharmaceuticals Inc. (VRCA) since IPO date, it would be worth $351.71 as of August 18, 2025 at a share price of $6.155. Whereas If you bought $1000 worth of Verrica Pharmaceuticals Inc. (VRCA) shares 5 years ago, it would be worth $719.04 as of August 18, 2025 at a share price of $6.155.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
GlobeNewswire Inc.
Aug 06, 2025 11:00 AM GMT
WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announ
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
GlobeNewswire Inc.
Jul 09, 2025 11:00 AM GMT
– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceut
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
GlobeNewswire Inc.
Jul 01, 2025 11:00 AM GMT
– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule – – Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) f